Navigation Links
Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

weeks of treatment with ISIS 301012.

The most common drug-related adverse events were painless mild to moderate injection site reactions. There was one possibly drug-related serious adverse event reported for the study: a patient in the 400 mg/dL cohort experienced fever more than 12 hours after receiving the first dose and subsequently dropped out of the study. This patient was not included in the per protocol analysis. In this high dose cohort, one patient had consecutive measurements of liver transaminases (ALT) above three times the upper limit of normal (3xULN); the maximal ALT observed in the study was 211 IU/L. Importantly, no patients evidenced liver chemistries that would suggest risk of liver injury (extremely high ALT or ALT elevations together with elevations in bilirubin greater than 2xULN). Patients in this study remain in follow-up.

According to John J.P. Kastelein, M.D., Ph.D., Chairman, Department of Vascular Medicine at the Academic Medical Center in Amsterdam, The Netherlands, lead investigator in the study, "ISIS 301012 continues to show exceptional promise as a new lipid-lowering agent. This study demonstrates that as an add-on therapy in patients on statins whose LDL-C levels are not adequately controlled, ISIS 301012 effectively enables patients to achieve target levels of LDL-C. This is an important clinical effect which, together its tolerability and lack of drug interactions, make ISIS 301012 an exciting drug for potential use in combination with other lipid-lowering therapies in the patients unable to derive sufficient benefit from available agents."

Mark Wedel, M.D., J.D., Isis' Chief Medical Officer, added, "ISIS 301012 is highly active and well tolerated in combination with statins, both in the routine high cholesterol population represented in this study, as well as in homozygous familial hypercholesterolemic patients on maximal concurrent lipid-lowering therapies. ISIS 301012 continues to perform to our highest ex
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Oct. 18, 2011 Phreesia, the patient check-in ... of electronic health records (EHR) software and solutions, ... Through this partnership, medical practices nationwide that use ... achieve a seamless patient check-in experience. The automated ...
... Melnik, President & CEO of PediaVisionJeff Mortensen, Vice President ... a revolutionary new vision screening device, which identifies vision ... October 20, Friday October 21 WHY: Spot is ... children across America.   Spot has an incredibly ...
Cached Medicine Technology:Phreesia and SOAPware Integrate to Improve Clinical Data and Streamline Workflow at Medical Practices 2Phreesia and SOAPware Integrate to Improve Clinical Data and Streamline Workflow at Medical Practices 3
(Date:7/10/2014)... Ticketability.com has a wide array of tickets for the ... San Diego are being added to the inventory. The star ... newly added September 28 show is drawing a great deal ... to view the selection of discounted seats at Ticketability.com. , ... to the general public on July 18 at 10:00 a.m. ...
(Date:7/10/2014)... 10, 2014 Thousands of researchers ... Copenhagen this July 13-17 to reveal the latest ... closer to breakthroughs in dementia science. The Alzheimer’s ... conference of its kind. , As part of ... a catalyst for generating new knowledge about dementia ...
(Date:7/10/2014)... One week ahead of its annual ... today it will extend compensation benefits to workers from ... workers displaced as a result of factory remediation, effective ... resulted in the closure of five factories for remediation. ... immediate safety concerns. In May, the Alliance—in a 50/50 ...
(Date:7/10/2014)... July 10, 2014 Register to download ... recently streamed the live webinar ‘Capitalizing on the Shifting ... a group of several M&A experts in the energy ... broader energy transaction marketplace. These experts shared their insights ... deal market in this sector has been revitalized. This ...
(Date:7/10/2014)... According to a new market research report "Man-Portable ... Application (Software Defined Radios, SATCOM, Encryption, Smartphones, Homeland ... Europe, the Middle East & ROW) - Forecast ... is estimated to be $30.15 billion in 2014 ... 5.56% to reach $39.52 billion by 2019 ...
Breaking Medicine News(10 mins):Health News:Paul McCartney Tickets for San Diego: Ticketability.com Announces Discounted Tickets for McCartney’s Tour Stop at Petco Park on September 28 2Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:Register to Download Merrill DataSite's Report: Capitalizing on the Shifting Sands of the Energy Market 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Portable Communication Systems Market Projected to Reach $39.52 Billion by 2019 - New Report by MarketsandMarkets 4
... Authentidate Holding Corp. (Nasdaq: ADAT ), ... workflow management services, today announced financial results for the ... Benjamin, President of Authentidate, stated, "Revenue growth slowed during ... conditions impacted our results. Although total revenues were ...
... of the most harmful forms of teen drug abuse with a hard-hitting ... ... Los Angeles, CA (PRWEB) February 12, 2009 -- Statistics show a dangerous ... office of the DEA announced this week that Phoenix high school students ...
... An investor group in Trinity,Biotech plc (Nasdaq: ... of,diagnostic products, is delighted that Jim Merselis has joined ... support for Mr. Merselis, the,group has scheduled a conference ... am PT) on Tuesday, February 17, 2009. , ...
... advancing the lives,of children and adults experiencing barriers to ... hit the slopes last weekend. Nearly,200 community members, volunteers ... a day of fun, competition and meeting new friends ... The event, at Trollhaugen in Dresser, ...
... SCAN Long Term Care and SCAN Health Plan Arizona, ... of Health Plans. "The new association intends to be ... here in Arizona," said Lescault. "As president I look ... the governor,s office in adjusting the state health budget ...
... CRANBURY, N.J., Feb. 12 Innophos Holdings, Inc. (Nasdaq: ... in North America, today announced the election of John ... is Executive Vice President and Chief Operating Officer of ... of highly engineered specialty chemicals, including polymer additives, catalysts ...
Cached Medicine News:Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 2Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 3Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 4Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 5Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 6Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 7Health News:Authentidate Holding Corp. Reports Fiscal 2009 Second Quarter Results 8Health News:Church of Scientology Fighting Teen Drug Abuse 2Health News:Second Annual Courage Cup Race Raises More Than $5,000 for Courage Center's Ski and Snowboard Program 2Health News:SCAN's Thomas Lescault Elected President of New Arizona Association of Health Plans 2Health News:Innophos Holdings, Inc. Elects John M. Steitz as New Independent Director 2
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
The MediLive ImageBox is the first, easy-to-use digital,recording device that integrates with the surgical microscope and video camera., ,It simplifies image capturing by burning the still imag...
With MediLive MindStream you can make, cut and edit digital videos, add commentaries and notes, and save them. MediLive MindStream - intuitive user interface and high-resolution monitor all in one....
... non-mydriatic fundus camera increases ... of fundus imaging. Compact, ... set the standard in ... a unique combination of ...
Medicine Products: